KEYNOTE 522 : Immunotherapy and chemo for early triple negative breast cancer

Overall survival results of the Phase III MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Highlights of Melanoma and Other Skin Tumours at ESMO 2019

Highlights of Lung Cancer at ESMO 2019

Individualised dosing of commonly used anti-cancer agents

Individualised dosing of commonly used anti-cancer agents

Presentation of case/condition: Review of novel agents licensed for use in the 21st century

Charting the course: Novel treatment options for patients with germline BRCA-mutated locally advanced or metastatic breast cancer

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis 

Multi-disciplinary perspectives on optimising patient outcomes in HER2-positive eBC

Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

SOLSTICE, a phase 3, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy

Safety and Efficacy of the Oral CXCR4 Inhibitor X4P-001 + Axitinib in Advanced Renal Cell Carcinoma Patients: An Analysis of Subgroup Responses by Prior Treatment 

Expanding the therapeutic opportunities in advanced prostate cancer

An update on the CheckMate 227

3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)